<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127215</url>
  </required_header>
  <id_info>
    <org_study_id>NCT-2017-0417</org_study_id>
    <nct_id>NCT03127215</nct_id>
  </id_info>
  <brief_title>Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors</brief_title>
  <acronym>NCT-PMO-1603</acronym>
  <official_title>A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Tumor Diseases, Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PharmaMar</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Tumor Diseases, Heidelberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients&#xD;
      with locally advanced/metastatic solid tumors that failed standard treatment and whose&#xD;
      molecular sequencing tumor profiles show homologous recombination repair (HRR) defects. The&#xD;
      primary objective is to show superior disease control rate in patients with HRR-deficient&#xD;
      tumors treated with olaparib and trabectedin compared to treatment according to current&#xD;
      guidelines (physician's choice). This trial aims to establish whether the PARP-dependency of&#xD;
      HRR-deficient tumors across entities can be exploited for therapeutic benefit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>At week 16 (after 5 cycles of study medication)</time_frame>
    <description>Randomized, open-label, multicenter phase-II study comparing olaparib in combination with trabectedin versus physician's choice. Primary efficacy endpoint is the disease control rate after 5 cycles.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from first administration of the IMP to time death from any cause until end of study (2.5 years)</time_frame>
    <description>defined as the time from first administration of the IMP to time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Time from first administration of the IMP to subjects end of trial (approximately month 6)</time_frame>
    <description>This endpoint includes all AEs, their severity, SAEs, the relation of AEs to the study treatment, dose modifications for toxicity and discontinuation of study treatment during the trial phase. Toxic effects will be graded according to the National Cancer Institute Common Toxicity Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>Before the first (week 0), at the third (week 8), and after the fifth treatment cycle (week 16)</time_frame>
    <description>Patient reported outcomes (PROs) including health-related quality of life (QoL) are calculated as the new European Organization for Research and Treatment of Cancer (EORTC). QLQ-C30 summary score recommended by teh EORTC Quality of Life Group. In addition, the EORTC QLQ function and symptom scores are calculated according to the actual EORTC Scoring Manual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>At week 16 (after 5 cycles of study medication)</time_frame>
    <description>Defined as the sum of complete remission (CR) and partial remission (PR) according to RECIST version 1.1 after 5 cycles of study medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Cancers With DNA Repair-Deficiency</condition>
  <arm_group>
    <arm_group_label>Arm E: Olaparib / Trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olaparib / Trabectedin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Physician's choice</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Physician's choice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib 150 mg tablet</description>
    <arm_group_label>Arm E: Olaparib / Trabectedin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Physician's choice</intervention_name>
    <description>treatment according to current guidelines</description>
    <arm_group_label>Arm C: Physician's choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <description>Trabectedin 1.1mg/m² infusional solution</description>
    <arm_group_label>Arm E: Olaparib / Trabectedin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Progressive locally advanced or metastatic malignancy&#xD;
&#xD;
          -  Prior administration of standard treatment for primary and relapsed malignancy&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status ≤1&#xD;
&#xD;
          -  Patients with central venous access device in place (central venous catheter or&#xD;
             porta-cath)&#xD;
&#xD;
          -  Age ≥18 and ≤70 years&#xD;
&#xD;
          -  Identification of defective DNA repair via HR&#xD;
&#xD;
          -  Adequate bone marrow, renal, and hepatic function&#xD;
&#xD;
          -  Hemoglobin ≥10 g/dl&#xD;
&#xD;
          -  Neutrophil count ≥1,500/mm3&#xD;
&#xD;
          -  Platelet count ≥100,000/µl&#xD;
&#xD;
          -  Bilirubin ≤1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤2.5 x ULN (≤5 x ULN in patients with hepatic tumor involvement)&#xD;
&#xD;
          -  Alkaline phosphatase ≤2.5 x ULN&#xD;
&#xD;
          -  PT-INR/PTT ≤1.5 x ULN&#xD;
&#xD;
          -  Albumin ≥25 g/l&#xD;
&#xD;
          -  Creatine kinase ≤2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine 1.5 mg/dl or creatinine clearance 51 ml/min&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Hematological malignancies and primary brain tumors.&#xD;
&#xD;
          -  Concurrent treatment in another interventional clinical trial&#xD;
&#xD;
          -  Prior treatment with PARP Inhibitors&#xD;
&#xD;
          -  Patients with platinum-refractory disease, defined as progressive disease during or&#xD;
             immediately after treatment with platinum based chemotherapy&#xD;
&#xD;
          -  Persistent toxicity (&gt; Grade 2 according to CTCAE 5.0)&#xD;
&#xD;
          -  Dementia or significant impairment of cognitive state&#xD;
&#xD;
          -  History of HIV infection&#xD;
&#xD;
          -  Clinical signs of active infection (&gt;Grade 2 according to CTCAE 4.03)&#xD;
&#xD;
          -  History of viral hepatitis (HBV or HCV)&#xD;
&#xD;
          -  Epilepsy requiring pharmacologic treatment&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Major surgical intervention 4 weeks prior to study inclusion&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs&#xD;
&#xD;
          -  Hematologic malignancy&#xD;
&#xD;
          -  QTc time prolongation &gt;500 ms or history of familial long-QT-syndrome&#xD;
&#xD;
          -  Heart failure NYHA III/IV&#xD;
&#xD;
          -  Severe obstructive or restrictive ventilation disorder&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A Inhibitors&#xD;
&#xD;
          -  Concomitant use of known strong CYP3A inducers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Froehling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCT / DKFZ Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Schlenk, MD</last_name>
    <phone>+49622156</phone>
    <phone_ext>6228</phone_ext>
    <email>studienzentrale@nct-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Fakultät der TU Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Richter, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Siveke, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Wagner, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Lena Illert, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Tumordiseases (NCT)</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Schlenk, MD</last_name>
      <phone>+49622156</phone>
      <phone_ext>6228</phone_ext>
      <email>studienzentrale@nct-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes-Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Kindler, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München-Großhadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Metzeler, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Schillerhöhe</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Georg Kopp, Prof Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Golf, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DNA Repair-Deficiency Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

